Evidence map›Paper›PMID 42088459›Full record

ArticleCancer management and research2026

Molecular Characterisations and the Association with Clinical Factors in

Xiang Li, Peiyan Zhao, Heran Cui, Tingting Zhang, Wenyu Sun, Hui Li

Abstract read
In one paragraph

Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiang LiTranslational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Malignant Tumor, Jilin Cancer Hospital, Changchun, People's Republic of China.
Peiyan ZhaoTranslational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Malignant Tumor, Jilin Cancer Hospital, Changchun, People's Republic of China.
Heran CuiDepartment of Pathology, Jilin Cancer Hospital, Changchun, People's Republic of China.ORCID 0000-0002-4728-3533
Tingting ZhangDepartment of Thoracic Oncology, Jilin Cancer Hospital, Changchun, People's Republic of China.
Wenyu SunDepartment of Thoracic Oncology, Jilin Cancer Hospital, Changchun, People's Republic of China.
Hui LiTranslational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Malignant Tumor, Jilin Cancer Hospital, Changchun, People's Republic of China.ORCID 0000-0003-2287-9493

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: From 2018 to 2024, 6,204 lung cancer patients received next‑generation sequencing (NGS) testing, among whom 102 were confirmed to be positive for Results: In this cohort, the prevalence of Conclusion: The new discoveries of

Indexed as

molecular characteristicsNGSNSCLCRET fusion

Identifiers

PMID42088459
PMCPMC13135900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.